Comprehensive Monogenic Obesity Panel
Use
This test is intended for individuals with severe, early-onset obesity or obesity associated with other relevant clinical features, who have a clinical or suspected diagnosis of non-syndromic or syndromic monogenic obesity. It helps in confirming a genetic cause by evaluating 52 genes associated with these conditions using next-generation sequencing (NGS) with copy number variation (CNV) analysis on the PGselect Platform.
Special Instructions
The test includes NGS with CNV analysis using the PGselect platform. Patients have the option of STAT testing, which provides faster results for an additional cost. The test is New York approved and must be ordered by a qualified healthcare provider. Proper informed consent and family members' informed consents need to be maintained on file as per the institution's guidelines.
Limitations
The test is developed and validated by PreventionGenetics following CAP and CLIA regulations, but it has not been cleared or approved by the FDA. The results should be interpreted considering the detailed clinical information provided by the ordering physician. Genetic counseling is recommended to discuss the implications of the results.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided